SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial
SAVE-Care (SGLT2i As Novel Gout Care) Trial
Who can join
Ages 18 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Provision of signed and dated informed consent form. 2. Fulfilling American College of Rheumatology \[ACR\]/European Alliance of Associations for Rheumatology \[EULAR\] gout criteria 3. 1+ gout flares in last 12 months 4. Serum urate level ≥ 6mg/dl 5. Males and females; Age 18-80 6. Willingness to adhere to the study intervention procedures. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Estimated Glomerular Filtration Rate \[eGFR\] \<20ml/min 2. Colchicine or nonsteroidal anti-inflammatory drug \[NSAID\] prophylaxis 3. active cardiovascular disease \[CVD\], type-1 diabetes 4. pregnant and lactating women 5. Presence of a condition(s) or diagnosis, either physical or psychological, or physical exam finding that precludes participation. \[History of ketoacidosis, end-stage or decompensated liver disease, active cancer\] 6. Use of anti-obesity drugs 7. Basal-bolus or multiple daily injection insulin regimens, or loop diuretics
About the study
SAVE-Care (Sodium Glucose Cotransporter-2 inhibitors \[SGLT2i\] As Novel Gout Care) Trial is a double-blind randomized placebo-controlled trial (RCT) designed to assess the effect of empagliflozin on serum urate \[SU\] levels of gout patients, as well as levels of highly-sensitivity C-reactive protein \[hsCRP\] and interleukin 6 \[IL-6\], and estimate gout flares over 3 months, in order to develop a full-scale RCT of clinical endpoints to directly inform gout care guidelines.
What is being tested
- Empagliflozin 10 mg (drug)
- Placebo (drug)
Sponsor: Massachusetts General Hospital · Participants: 60 · Started: Jul 1, 2026
Contact the study team
- Ana D Fernandes, MA · Phone: 617-643-2140
Official record on ClinicalTrials.gov — NCT06674109
Locations in the U.S.
| Massachusetts | Massachusetts General Hospital, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.